证券研究报告 交通运输 | 物流 非金融|首次覆盖报告 hyzqdatemark 2026 年 02 月 25 日 证券分析师 孙延 SAC：S1350524050003 sunyan01@huayuanstock.com 王惠武 SAC：S1350524060001 wanghuiwu@huayuanstock.com 曾智星 SAC：S1350524120008 zengzhixing@huayuanstock.com 张付哲 SAC：S1350525070001 zhangfuzhe@huayuanstock.com 高树根 gaoshugen@huayuanstock.com 市场表现： | 基本数据 | | 2026 | 年 | 02 | 月 24 | 日 | | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | 12.90 | | | 一 年 内 最 / 最 | 高 | 低 | | | | | | （元） | | | | | 13.35/9.00 | | | 总市值（百万元） | | | | | 5,901.62 | | | ...

Investment Rating - The report assigns a "Buy" rating for Runben Co., Ltd. (603193) as a new benchmark in the maternal and infant care sector [1]. Core Insights - Runben Co., Ltd. has shown steady performance with a focus on the baby mosquito repellent market, gradually expanding into baby care and plant essential oils, forming a multi-category daily chemical ecosystem. The core categories of mosquito repellent and baby care account for over 85% of revenue, driving continuous growth in revenue and profit [7][24]. - The global and Chinese markets for mosquito repellent and baby care products are expected to grow steadily, with the children's mosquito repellent market projected to reach 1.795 billion yuan by 2024, and the baby care market expected to reach 32.9 billion yuan in the same year [7][40]. - Runben's integrated research, production, and sales model creates long-term competitive barriers, with plans to invest 700 million yuan in smart factories and 600 million yuan to expand R&D and production bases [7][24]. Summary by Sections 1. Business Growth and Performance - Runben Co., Ltd. has transitioned from a single-category brand focused on mosquito repellent to a multi-scenario daily chemical enterprise, leveraging user assets and integrated operations [16]. - The company has achieved a compound annual growth rate (CAGR) of 31.32% in revenue from 582 million yuan in 2021 to 1.318 billion yuan in 2024, with net profit increasing from 121 million yuan to 300 million yuan in the same period [7][24]. - The revenue structure is concentrated, with the baby care segment's share increasing from 37.22% in 2021 to 52.36% in 2024, while the mosquito repellent segment stabilized between 31% and 33% [22]. 2. Industry Landscape and Trends - The global children's mosquito repellent market is expected to grow at a CAGR of 4.26% from 2023 to 2027, while the Chinese market is projected to grow at approximately 6.1% during the same period [7][33]. - The baby care market in China is anticipated to reach 32.9 billion yuan by 2024, with a CAGR of 7.97% from 2023 to 2027, indicating strong growth potential [40][42]. - The competitive landscape in the mosquito repellent market shows a concentration of top brands, with the top 10 brands holding significant market shares, reflecting a strong competitive environment [34]. 3. Competitive Advantages - Runben Co., Ltd. maintains a high sales net profit margin, with figures ranging from 18.69% to 22.77% from 2021 to 2025, indicating strong operational control and market positioning [54]. - The company has a superior inventory turnover efficiency, with inventory turnover days decreasing to 66.29 days in 2025, showcasing effective supply chain management [57]. - The accounts receivable turnover days are also favorable, with a notable efficiency in cash collection, primarily due to the online direct sales model [58].

农林牧渔行业 买入 （维持） 一体化龙头 竞争优势显著 深 度 研 深 度 研 牧原股份（002714）深度报告 2026 年 2 月 25 日 | 魏红梅 邮箱：whm2@dgzq.com.cn 公 公 司 司 研 研 究 究 主要数据 2026 | | --- | | SAC 执业证书编号： | | S0340513040002 | | 电话：0769-22119410 | | 年 2 月 24 日 | | 收盘价（元） 44.56 | | 总市值（亿元） 2,556.28 | | 总股本（百万股） 5,736.72 | | 流通股本（百万股） 4,082.75 | | ROE(TTM) 29.24% | | 12 月最高价（元） 58.65 | | 12 月最低价（元） 35.01 | 资料来源：iFinD，东莞证券研究所 投资要点： 本报告的风险等级为中风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 SAC 执业证书编号： 公司是我国生猪养殖一体化龙头。公司始创于1992年，于2012年养猪事 业走出河南，2014年在深交 ...

Investment Rating - The investment rating for the company is "Buy" [6][19]. Core Insights - The report highlights that the traditional electronic fabric prices are expected to rise significantly in February, driven by a shortage of traditional fabric due to the conversion of weaving machines to produce AI specialty fabrics. As the largest producer of traditional fabric, the company stands to benefit, with every 1 yuan increase in electronic fabric prices potentially adding 1 billion yuan to the company's profits [2][12]. - The company is projected to see a substantial increase in earnings per share (EPS) for 2025-2027, with estimates raised to 0.88 yuan, 1.24 yuan (+0.19), and 1.39 yuan (+0.19) respectively. The target price has been adjusted to 37.16 yuan based on a comparable company PE of 29.97 times for 2026 [12][14]. Financial Summary - Total revenue is forecasted to grow from 14,876 million yuan in 2023 to 23,351 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 10.7% [4]. - Net profit attributable to the parent company is expected to recover from 3,044 million yuan in 2023 to 5,552 million yuan in 2027, with a notable increase of 44.8% in 2025 and 40.1% in 2026 [4]. - The company's earnings per share (EPS) is projected to increase from 0.76 yuan in 2023 to 1.39 yuan in 2027 [4]. - The return on equity (ROE) is expected to improve from 10.6% in 2023 to 14.6% in 2027 [4]. Market Data - The current stock price is 27.62 yuan, with a target price of 37.16 yuan, indicating a potential upside [6][7]. - The company has a total market capitalization of 110,567 million yuan and a total share capital of 4,003 million shares [7][8]. - The stock has shown significant performance, with a 52-week price range of 11.01-28.30 yuan and an absolute increase of 149% over the past 12 months [11][12].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [9]. Core Views - The company is positioned to benefit significantly from the global power investment cycle, particularly in the high-voltage transformer sector, with a strong technical barrier and plans for international expansion [9][7]. - The company achieved a record high in transformer exports in 2025, with a total export value of USD 9.036 billion, reflecting a year-on-year growth of 34.9% [1]. - The company has established a wholly-owned subsidiary in Saudi Arabia, which is expected to accelerate its overseas business expansion and alleviate domestic production capacity constraints [8]. Summary by Relevant Sections Company Overview - The company is recognized as a "single champion" in electromagnetic wire products, with significant technological advantages and a leading market position in high-voltage applications [7]. - The company has a stable customer base in the U.S. and has seen substantial growth in overseas revenue, which reached RMB 499 million in 2024, a year-on-year increase of 109% [7]. Financial Projections - The company is projected to achieve revenues of RMB 29.01 billion, RMB 42.11 billion, and RMB 49.82 billion for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 40.00%, 45.15%, and 18.30% [9]. - The expected net profit attributable to the parent company for the same years is RMB 1.11 billion, RMB 1.63 billion, and RMB 2.07 billion, with growth rates of 9.71%, 46.98%, and 26.61% [9][10].

国内超细纤维龙头，技术突破开启转型新 ——聚杰微纤首次覆盖报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 盛开(分析师) | 021-23154510 | shengkai@gtht.com | S0880525040044 | | 钟启辉(研究助理) | 021-23185686 | zhongqihui@gtht.com | S0880125042254 | 本报告导读： 公司作为国内超纤龙头，超纤主业转型仿皮面料、无尘洁净制品等高端工业用途迎 来价值拐点。深度布局固态电池、具身智能等前沿科技，捕捉未来发展机会。 投资要点： | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | [Table_Finance] 财务摘要(百万元) | | | | | | | 营业总收入 | 685 | 600 | 592 | 653 | 749 | | --- | --- | --- | --- | --- | --- ...

[Table_Title] 前沿生物：小核酸领域的冉冉新星 [Table_scodeMsg1] 公司研究丨深度报告丨前沿生物-U（688221.SH） %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 前沿生物是一家聚焦于具备技术和专利壁垒，以差异化优势的思路进行药物开发的创新药企 业，近年来逐步形成了长效抗 HIV 药物+新技术小核酸药物+高端仿制药的产品格局。公司目前 已储备了丰富的小核酸药物管线，涵盖了 IgA 肾病、血脂异常等慢病适应症。其中，FB7013 与 FB7011 均为靶向补体系统的设计，靶点选择具备 FIC 潜力。此外，公司自主研发的长效抗 HIV 病毒融合抑制剂艾可宁的放量趋势稳健，并同时储备了长效抗 HIV 的在研新药，未来有望形成 新的产品组合，持续巩固公司在艾滋病领域的竞争优势。 分析师及联系人 [Table_Author] 彭英骐 刘长洪 SAC：S0490524030005 SAC：S0490525070007 SFC：BUZ392 请阅读最后评级说明和重要声明 2 / 30 %% %% %% %% r ...

云服务 分析师：唐月 登记编码：S0730512030001 tangyue@ccnew.com 021-50586737 实现对即将盈利孙公司全资控股，REIT 扩募成为持续的融资通道 ——润泽科技(300442)点评报告 证券研究报告-中报点评 买入(维持) 市场数据(2026-02-24) | 收盘价(元) | 86.80 | | --- | --- | | 一年内最高/最低(元) | 93.13/42.06 | | 沪深 300 指数 | 4,707.54 | | 市净率(倍) | 10.47 | | 流通市值(亿元) | 1,413.43 | | 基础数据(2025-09-30) | | | 每股净资产(元) | 8.29 | | --- | --- | | 每股经营现金流(元) | 1.69 | | 毛利率(%) | 48.11 | | 净资产收益率_摊薄(%) | 34.73 | | 资产负债率(%) | 62.53 | | 总股本/流通股(万股) | 163,434.36/162,837.40 | | B 股/H 股(万股) | 0.00/0.00 | 个股相对沪深 300 指数表现 -38% ...

上 市 公 司 公 司 研 究 / 公 司 深 2026 年 02 月 25 日 桐昆股份 (601233) 报告原因：强调原有的投资评级 投资要点： 市场数据： 2026 年 02 月 24 日 收盘价（元） 24.51 一年内最高/最低（元） 24.80/9.63 市净率 1.6 股息率%（分红/股价） 0.41 流通 A 股市值（百万元） 58,723 上证指数/深证成指 4,117.41/14,291.57 注："股息率"以最近一年已公布分红计算 | 基础数据: | 2025 年 09 月 30 日 | | --- | --- | | 每股净资产（元） | 15.75 | | 资产负债率% | 66.30 | | 总股本/流通 A 股（百万） | 2,400/2,396 | | 流通 B 股/H 股（百万） | -/- | dingying@swsresearch.com 联系人 邵靖宇 A0230524080001 shaojy@swsresearch.com 本研究报告仅通过邮件提供给 中庚基金 使用。1 ⚫ 风雨四十载铸就全球长丝巨头，产业链一体化优势稳固。公司成立 40 年来专注涤纶长丝产 业 ...

Investment Rating - The report assigns an "Buy" rating for the company, marking the first coverage of its stock [4]. Core Insights - The company, Maiwei Biopharmaceuticals, is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and clear innovation direction, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-research and business development (BD), leveraging its unique technology platforms and differentiated product pipelines to create value [2][4]. - The revenue forecast for the company shows significant growth, with projected revenues of 674 million RMB in 2025, 1.163 billion RMB in 2026, and 1.273 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of 238% from 2024 to 2025 [4]. Summary by Sections Company Overview - Maiwei Biopharmaceuticals has transitioned from a "generic-innovative" model to a "global innovation" approach, with plans for a Hong Kong IPO to support its sustainable development and international expansion [9]. - The company has a stable shareholding structure and an experienced management team, with a focus on drug development and commercialization [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work in synergy to achieve rapid innovation and differentiation [22][23]. - The pipeline is rich, with a focus on oncology products for immediate returns and anti-aging products for long-term growth [28]. Business Development Strategy - Maiwei has adopted a diversified and integrated approach to business development, forming partnerships to enhance product value and cash flow [4][19]. - The company is actively expanding its biosimilar drug business, which is crucial for cash flow, while also pursuing global market opportunities [4][19]. Financial Projections and Valuation - The company is expected to see a significant improvement in cash flow due to the anticipated success of its BD initiatives and the commercialization of its biosimilars [4]. - The estimated equity valuation of the company is 26.845 billion RMB, indicating that the current market valuation is undervalued [4].